COMPANY PROFILE

Anjarium Biosciences AG

Anjarium Biosciences is a transforming exosomes from cellular message couriers to potent therapeutic carriers for debilitating diseases

Zurich, SwitzerlandFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Anjarium Biosciences AG

Anjarium Biosciences, headquartered in Switzerland, specializes in advanced synthetic DNA technology designed to enhance mRNA production and gene therapy. The company serves researchers and manufacturers in the life sciences sector, providing customizable DNA constructs that accelerate the discovery and delivery of genetic medicines. Operating in the biotechnology market, Anjarium's business model focuses on delivering high-quality synthetic DNA products that optimize R&D and manufacturing workflows. Revenue is generated through partnerships with leading life science investors and the sale of proprietary DNA and resin products. Anjarium's technology enables superior yield, purity, and potency compared to traditional methods, making it a key player in the genetic medicine landscape.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Zurich, Switzerland
Employees: 6
Open positions: None listed
Dealroom signal: 63.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, DNA, Synthetic Biology, RNA, Digital Therapeutics, Biotech and Pharma, Techbio, Techbio Drug Discovery, DT and LS, science-based
Business model: Manufacturing
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Sep 2021	$61M	$244M	Abingworth · Gimv · Omega Funds · Pfizer Ventures	—
SUPPORT PROGRAMOther financing	Dec 2017	$0	—	Grow Cluster Wädenswil	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Anjarium Biosciences AG website traffic

Latest recorded traffic for Anjarium Biosciences AG is 220 monthly website visits, down 73.2% over the last three months. Anjarium Biosciences AG's team grew 0% over the past year.

Latest monthly visits220 3-month web change-73.2% 1-year team growth0%

Monthly website visitsFeb 2021–Dec 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NBNew BiologixEngineered cell line technology that produces safe and effective AAV drugs for gene therapy, making treatments more affordable and accessible	Epalinges, Switzerland	Operational	25	$50M	$200M
CRCradleAI-powered protein design and engineering platform.	Amsterdam, Netherlands	Operational
TGTouchlight GeneticsDevelops a DNA production platform designed for the development of DNA vaccines for oncology and infectious diseases	London, United Kingdom	Operational
NUNucleraMaking biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day	Cambridge, United Kingdom	Operational
EVEvonetixUr desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use synthetic biology on a scale not currently possible	Cambridge, United Kingdom	Operational
INInVirtuoLabsModular AI solutions accelerating drug discovery with predictive models and generative simulations	Lugano, Switzerland	Operational
ABAvenue BiosciencesInnovative protein engineering solutions integrating biologics and machine learning for therapeutic advancements	Palo Alto, United States	Operational
PBPattern BiosciencesBuilds biomolecular computers that run molecular programs in cells to treat cancer and other diseases	South San Francisco, United States	Operational